APAS Data Explorer
  • View maps
  • About the data
  • Links
    • APAS
Disclaimer The content contained in this Data Explorer is published in good faith by the Australian Commission on Safety and Quality in Health Care for information purposes only. The content is not intended to provide guidance on particular healthcare choices. Users should exercise their own skill and care when using this content and carefully evaluate its accuracy, currency, completeness and relevance for their purposes. You should contact your healthcare provider on particular healthcare choices. The Australian Commission on Safety and Quality in Health Care and the Australian Centre for Disease Control do not accept any legal liability for any injury, loss or damage incurred by the use of, or reliance on, this information.

Last updated 7 November 2025

Notes:

  • n = total number of isolates
  • %R = percentage of resistant isolates

About AURA:

The Commission's Antimicrobial Use and Resistance in Australia (AURA) Project contributes to the AURA surveillance program, which is coordinated and funded by the the Australian Centre for Disease Control (CDC), with contributions from the states, territories and private pathology services as part of the collection and analysis of their data. AURA data on antimicrobial resistance (AMR) inform strategies for infection prevention and control and antimicrobial stewardship.

About APAS:

Australian Passive AMR Surveillance (APAS) is coordinated by the Commission in collaboration with Queensland Health. APAS is a key component of the AURA surveillance program funded by the CDC. APAS collects, analyses and reports on AMR data from routine susceptibility testing results from participating public and private pathology services across Australia. APAS contains de-identified patient-level AMR data collected from hospitals, aged care, and community settings across Australia.

About the data:

  • Data represent clinical infections
  • Data from isolates detected in infection control and environmental sampling were excluded
  • Data were only included where there were at least 30 isolates for each analysis
  • Analyses were conducted only when the proportion of isolates that were tested against a single antimicrobial was at least 75%
  • Only the first isolate for the first specimen of each specimen type per year was included in the dataset for analyses
  • APAS data report on antimicrobials tested by using either the European Committee on Antimicrobial Susceptibility Testing (EUCAST) or the Clinical and Laboratory Standards Institute (CLSI) or the Calibrated Dichotomous Sensitivity (CDS) methods that were used by the pathology service
  • APAS provides categorical data (susceptible, intermediate [susceptible increased exposure], resistant) based on interpretive criteria as determined by the participating pathology service
  • Data were mapped to Australian Statistical Area Levels 3 and/or 4 (SA3 and SA4) based on postcode of residence (where known), depending on the number of isolates available. SA4s are the largest sub-state regions; they are geographic areas built from whole SA3s
  • Data are not available from Northern Territory, except where a resident received pathology services in another jurisdiction
  • Data from Mater Pathology Queensland are not available from December 2024.

For more information about APAS and methodology and consideration for analyses, see Appendices 1 and 2 of Australian Passive AMR Surveillance: An update of resistance trends in multidrug-resistant organisms – 2006 to 2023. Data on additional resistances will be added to the Data Explorer over time.